Sort
82,697 grants matching “vaccine development”
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
$1,000,000Michael David Alpert · Emmune, Inc · R44 · FY2023 · AI
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
$1,000,000Keith Wycoff · Planet Biotechnology, Inc. · R44 · FY2023 · AI
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Timothy Rodell · Globeimmune, Inc. · R01 · FY2014 · AI
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2014 · AI
A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine
$1,000,000Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2017 · AI
International Training in AIDS-Related Epidemiology
$1,000,000Harvard University (Sch Of Public Hlth) · D43 · FY2003 · TW
Low cost molecular assay for HIV
$1,000,000Bertrand Lemieux · Biohelix Corporation · R44 · FY2009 · AI
Plasmodium vivax recombinant CS protein vaccine for malaria
$1,000,000B. Kim Lee Sim · Protein Potential, Llc · R44 · FY2011 · AI
Identification and validation of influenza host factors as therapeutic targets
$1,000,000David E Root · Massachusetts Institute Of Technology · U01 · FY2007 · AI
Universal Attenuated Sporozoite Vaccine and Challenge System
$1,000,000Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2012 · AI
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups
$1,000,000Gregory Robert Moe · Omvax, Inc. · R44 · FY2021 · AI
Treatment of Peanut Allergy with Intradermal Administration of ASP0892 (ARA-LAMP-vax): A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study
$1,000,000Robert A Wood · Johns Hopkins University · UM2 · FY2020 · AI
Pre-clinical Development of a Broad Spectrum Antiviral Compound to Treat Human Pa
$1,000,000Christopher Fisher · Nanovir, Llc. · R42 · FY2010 · AI
An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC
$1,000,000Jennifer A Schwartz · Profectus Biosciences, Inc. · R44 · FY2016 · AI
Transgenic Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture
$1,000,000Peter F. Billingsley · Sanaria, Inc. · R44 · FY2013 · AI
Enhanced Surveillance for New Vaccine Preventable Diseases
$1,000,000Janet A Englund · Seattle Children'S Hospital · U01 · FY2019 · IP
DNA prime / rVSV boost Multi-Antigen Universal Influenza Vaccine
$1,000,000Kenneth C Bagley · Orlance, Inc. · R44 · FY2021 · AI
IP23-006 VIMP: A Discourse-Aware, Community-Informed Toolkit to Predict Virality and Impact of Vaccine Misinformation Contents
$1,000,000Mark Stenius Roberts · University Of Pittsburgh At Pittsburgh · U01 · FY2023 · IP
COMmunity Mistrust and Institutional Trustworthiness to advance health EQuity research (COMMIT-EQ)
$1,000,000Claudia Rose Baquet · University Of Maryland Baltimore · U01 · FY2022 · FD
Exposure to PFNA and other PFAS in drinking water and associations with health-related outcomes in Gloucester County NJ
$1,000,000Robert John Laumbach · Rbhs-School Of Public Health · U01 · FY2020 · TS
New Vaccine Surveillance Network
$1,000,000John V Williams · University Of Pittsburgh At Pittsburgh · U01 · FY2017 · IP
Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.
$1,000,000Christopher H Clegg · Tria Bioscience Corporation · R44 · FY2011 · AI
Enhanced Surveillance for New Vaccine Preventable Diseases
$1,000,000Janet A Englund · Seattle Children'S Hospital · U01 · FY2017 · IP
Vaccine Strategies for Candidal Infections
$1,000,000John P Hennessey · Novadigm Therapeutics, Inc. · R42 · FY2010 · AI
Non-Human Primate Lymphoid Organ Chips for Vaccine Assessment
$1,000,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2024 · AI